Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
8.165-8.4649p
I agree about the undervalued and hope the 50% comes about too
8.00-8.40p
Out on 7 June 2024
Expect a break-out of 50% in SP by end of next week.
This share is totally undervalued
in my opinion - but do your own research
Good questions Peter
Https://www.investormeetcompany.com/investor/meeting/final-results-90/questions
When will we get approval to operate in the USA?
When can we expect to see profit - as the market likes profitable companies?
With Steriwave gaining recognition throughout the World why not get a larger company involved to get quicker approval of USA requirements
Which of your 7 projects will be next to be implemented?
7.42-7.9p
Ondine Biomedical Inc. (AIM: OBI) announces that it will publish its audited results for the year ended 31 December 2023 ("Full Year Results") and Annual Report 2023 on 7 June 2024. Dr. Nicolas Loebel, President and Chief Technology Officer of the Company, will provide a live presentation relating to the Full Year Results via Investor Meet Company on 10 June 2024, 16:30 BST (08:30 Pacific time).
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9 June 2024, 09:00 BST (01:00 Pacific time), or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet ONDINE BIOMEDICAL INC. via: https://www.investormeetcompany.com/ondine-biomedical-inc/register-investor
Investors who already follow ONDINE BIOMEDICAL INC. on the Investor Meet Company platform will automatically be invited.
A full overview of the 2023 fiscal year will be presented in the Annual Report 2023, which will be available on the Company's website on 7 June 2024. at: www.ondinebio.com/investors/reports-documentation/. The slides and recording of the live presentation will be posted to the same webpage as soon as available following the presentation, no later than 11 June 2024.
The Company's 2024 Annual General Meeting is being held virtually on 28 June 2024 at 16:00 BST (08:00 Pacific time); registered shareholders and their duly appointed proxyholders can attend the Meeting online via the link being provided in the Notice of Meeting.
Shares in the Vancouver-based life sciences company were up 37% at 7.00 pence each in London on early Friday afternoon. The stock is down 63% over the past 12 months.
Ondine announced a proposed fundraise for no less than GBP3 million though a placing and subscription offer of new shares at an issue price of 7p each.
The issue price represents a 40% premium to the company's Thursday closing share price of 5.00p.
The company has already received interest in the subscription offer from the majority of its directors, representing a total of around GBP290,000.
Proceeds from the fundraise will provide general working capital, Ondine said, but also support phase 3 clinical trial preparations as the company accelerates the commercialisation of its Steriwave antimicrobial.
In addition, the GBP3 million will extend Ondine's financial runway to at least the third quarter of 2024, the company said.
Chief Executive Officer Carolyn Cross said: "We are pleased to have the support of existing and new investors through this fundraising which meets our near-term working capital needs and assists our rapid commercial growth rate. This funding will take us forward commercially and further our discussions with industry partners on our clinical, financial, and global distribution objectives."
By Hugh Cameron, Alliance News reporter
Old news Peter, you just need to post this link
All info on
https://ondinebio.com/investors/
As a result of Ondine’s positive clinical data, growing sales momentum and recent commercial success, the Company has been approached by several multinational companies in the hospital supply, wound care, and infection control industries. The Company is currently in a process of progressing discussions on distribution collaborations with potential partners. While these discussions have been constructive, there is no certainty that a distribution agreement will materialize from any of these discussions. Management believes that distribution partnerships have the potential to generate earlier income for Ondine in the form of time-based territorial license payments and to accelerate sales and income generation for the Company through faster market penetration and greater geographical reach. The Company’s 2023 investments in manufacturing capacity upgrades combined with a significant COGS reduction program support larger-scale rollout and increased gross margins required by any potential partners. The latest generation light diffuser is reducing the cost of goods for our Steriwave testing kits by 46 per cent.
But also support phase 3 clinical trial preparations as the company accelerates the commercialisation of its Steriwave antimicrobial.
While we are currently focused on nasal decolonisation to prevent healthcare-associated infections, Steriwave is just the first of seven major market opportunities for our platform technology. In due course, pipeline products targeting the treatment of burns, wounds, chronic sinusitis, ventilator-associated pneumonia, and fungal infections will leverage our regulatory filings and the clinical successes related to our nasal decolonisation product."
Slowly emerging from months of inactivity (share price wise)
yet steriwave has not been slow in taking on new work-places,
such as getting involved in ICU and new hospitals have been added
With the threat of antibiotic-resistant HAIs increasing year-on-year, there is a growing need for effective antimicrobials which do not generate resistance. Antimicrobial resistance (AMR) is responsible for 1.27 million deaths a year and is one of humanity's most urgent global public health threats.[1] Ondine's Steriwave light-activated antimicrobial technology is highly effective against all types of pathogens-viruses, bacteria and fungi-including those that cause HAIs, eve
Just looked into the Fleming initiative ,after it appeared on a social media page, The head of that and initiative and partners … going to start loading up here (and a competitor) that both have reduced SP recently , definitely worth a go now, usual caveat applies
Ondine Biomedical (LON: OBI): A recent report from the European Centre for Disease Prevention and Control (ECDC) helps underscore the need for Ondine's light-activated antimicrobial technology, a much-needed innovation in the face of growing antibiotic resistance. The report reveals an alarming increase in antibiotic use and rising resistance and finds that 4.3 million patients in EU/EEA hospitals are affected by healthcare-associated infections (HAIs). Ondine's technology offers a promising solution, now used across Canada and in the NHS. The technology kills all types of pathogens without causing resistance, addressing a critical gap in the fight against antimicrobial resistance (AMR).
The report, "Point prevalence survey of healthcare-associated infections and anti-microbial use in European acute care hospitals - 2022-2023", showed that antibiotic usage has increased since the last report in 2016-17. In 2022-23, 35.5% of patients were found to have received at least one antimicrobial agent, compared to 32.9% in 2016-17. This increase in antibiotic use is particularly concerning because one in three microorganisms causing HAIs were found to be resistant to antibiotics, leaving doctors with fewer options to treat patients effectively.
ECDC Director Dr. Andrea Ammon said: "Healthcare-associated infections pose a significant challenge to patient safety in hospitals throughout Europe. These recent numbers highlight the urgent need for further actions to mitigate this threat. By prioritising infection prevention and control policies and practices, as well as antimicrobial stewardship and improving surveillance, we can effectively combat the spread of these infections and protect the health of patients across the EU/EEA."
With the threat of antibiotic-resistant HAIs increasing year-on-year, there is a growing need for effective antimicrobials which do not generate resistance. Antimicrobial resistance (AMR) is responsible for 1.27 million deaths a year and is one of humanity's most urgent global public health threats.[1] Ondine's Steriwave light-activated antimicrobial technology is highly effective against all types of pathogens-viruses, bacteria and fungi-including those that cause HAIs, eve
Just bought some more in this. I think this could be huge, and is totally under the radar.
S a result, the total raised in its Placing and Subscription (the
"Fundraising") is now approximately £3.54 million (C$6.07 million), at the
Issue Price of 7 pence per New Common Share.
Further details on the Fundraising are included in the Company's announcement
of 8.00 a.m. on 3 May 2024.
The total gross proceeds of the Fundraising are approximately £3.54 million
(C$6.07 million) and the estimated net proceeds are expected to be
approximately £3.37 million (C$5.70 million).
Truly a sleeping giant
Hopefully over the next few weeks and months this will steadily rise i reckon this could be a sleeping giant
Thank you Steriwave
Was it only a dream?
Only the market will say